Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE III, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MARIMASTAT IN PATIENTS WITH MINIMAL DISEASE STAGE III NON-SMALL CELL LUNG CANCER

NCT00002911 is registered in ClinicalTrials.gov with ILEX Oncology Services, Incorporated as lead sponsor.

NCT NCT00002911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00002911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE III, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MARIMASTAT IN PATIENTS WITH MINIMAL DISEASE STAGE III NON-SMALL CELL LUNG CANCER
Lead sponsor
ILEX Oncology Services, Incorporated
Phase
Phase 3
Overall status
Completed
Start date
December 31, 1996
Completion date
May 31, 2004
Enrollment
Not reported
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer